Back to Search Start Over

Neutron-activated, plasmonically excitable Fe-Pt-Yb 2 O 3 nanoparticles delivering anti-cancer radiation against human glioblastoma cells.

Authors :
Seemann KM
Kovács A
Schmid TE
Ilicic K
Multhoff G
Dunin-Borkowski RE
Michelagnoli C
Cieplicka-Oryńczak N
Jana S
Colombi G
Jentschel M
Schneider CM
Kuhn B
Source :
IScience [iScience] 2023 Aug 18; Vol. 26 (9), pp. 107683. Date of Electronic Publication: 2023 Aug 18 (Print Publication: 2023).
Publication Year :
2023

Abstract

Magnetic nanoparticles can be functionalized in many ways for biomedical applications. Here, we combine four advantageous features in a novel Fe-Pt-Yb <subscript>2</subscript> O <subscript>3</subscript> core-shell nanoparticle. (a) The nanoparticles have a size of 10 nm allowing them to diffuse through neuronal tissue. (b) The particles are superparamagnetic after synthesis and ferromagnetic after annealing, enabling directional control by magnetic fields, enhance NMRI contrast, and hyperthermia treatment. (c) After neutron-activation of the shell, they carry low-energetic, short half-life β-radiation from <superscript>175</superscript> Yb, <superscript>177</superscript> Yb, and <superscript>177</superscript> Lu. (d) Additionally, the particles can be optically visualized by plasmonic excitation and luminescence. To demonstrate the potential of the particles for cancer treatment, we exposed cultured human glioblastoma cells (LN-18) to non-activated and activated particles to confirm that the particles are internalized, and that the β-radiation of the radioisotopes incorporated in the neutron-activated shell of the nanoparticles kills more than 98% of the LN-18 cancer cells, promising for future anti-cancer applications.<br />Competing Interests: The authors declare no competing interests.<br /> (© 2023 The Author(s).)

Details

Language :
English
ISSN :
2589-0042
Volume :
26
Issue :
9
Database :
MEDLINE
Journal :
IScience
Publication Type :
Academic Journal
Accession number :
37680485
Full Text :
https://doi.org/10.1016/j.isci.2023.107683